This company has been acquired
Liminal BioSciences Future Growth
Future criteria checks 0/6
We currently don't have sufficient analyst coverage to forecast growth and revenue for Liminal BioSciences.
Key information
n/a
Earnings growth rate
n/a
EPS growth rate
Biotechs earnings growth | 25.1% |
Revenue growth rate | n/a |
Future return on equity | n/a |
Analyst coverage | None |
Last updated | n/a |
Recent future growth updates
No updates
Recent updates
Liminal transfers to Nasdaq Capital Market, gets more time to comply with listing rule
Sep 02Liminal BioSciences ends CDMO agreement for $33M cost savings
Aug 25Liminal BioSciences discontinues fezagepras development
Jul 21FDA grants approval to Liminal BioSciences' Ryplazim treatment
Jun 04Liminal shares slide after plans to stop fezagepras development
May 28Liminal Biosciences subsidiary receives FDA nod for US-based plasma collection centre
Jan 12Liminal BioSciences Inc. 2020 Q3 - Results - Earnings Call Presentation
Nov 13FDA extends review period for Liminal Bio's Ryplazim application
Nov 09In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Liminal BioSciences has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
6/30/2023 | 0 | -28 | -36 | -36 | N/A |
3/31/2023 | 1 | -26 | -35 | -35 | N/A |
12/31/2022 | 0 | -29 | -32 | -32 | N/A |
9/30/2022 | 0 | -31 | -38 | -38 | N/A |
6/30/2022 | 1 | -36 | -84 | -84 | N/A |
3/31/2022 | 0 | -42 | -86 | -86 | N/A |
12/31/2021 | 1 | -44 | -100 | -100 | N/A |
9/30/2021 | 1 | -48 | -114 | -114 | N/A |
6/30/2021 | 1 | -49 | -75 | -74 | N/A |
3/31/2021 | 1 | -35 | -75 | -74 | N/A |
12/31/2020 | 1 | -48 | -78 | -76 | N/A |
9/30/2020 | 1 | -75 | -87 | -85 | N/A |
6/30/2020 | 2 | -94 | -86 | -85 | N/A |
3/31/2020 | 3 | -232 | -109 | -105 | N/A |
12/31/2019 | 1 | -150 | -104 | -99 | N/A |
9/30/2019 | -8 | -299 | -95 | -89 | N/A |
6/30/2019 | 3 | -298 | -90 | -84 | N/A |
3/31/2019 | 23 | -194 | -73 | -68 | N/A |
12/31/2018 | 25 | -197 | -88 | -82 | N/A |
9/30/2018 | 43 | -131 | -91 | -85 | N/A |
6/30/2018 | 55 | -118 | -112 | -105 | N/A |
3/31/2018 | 39 | -115 | -128 | -120 | N/A |
12/31/2017 | 22 | -112 | -133 | -123 | N/A |
9/30/2017 | 37 | -109 | -139 | -129 | N/A |
6/30/2017 | 16 | -119 | -130 | -118 | N/A |
3/31/2017 | 16 | -112 | N/A | -114 | N/A |
12/31/2016 | 16 | -101 | N/A | -98 | N/A |
9/30/2016 | 26 | -74 | N/A | -76 | N/A |
6/30/2016 | 28 | -58 | N/A | -66 | N/A |
3/31/2016 | 28 | -48 | N/A | -59 | N/A |
12/31/2015 | 25 | -51 | N/A | -46 | N/A |
9/30/2015 | 21 | -31 | N/A | -42 | N/A |
6/30/2015 | 18 | -41 | N/A | -36 | N/A |
3/31/2015 | 19 | -5 | N/A | -27 | N/A |
12/31/2014 | 23 | 6 | N/A | -26 | N/A |
9/30/2014 | 18 | -10 | N/A | -25 | N/A |
6/30/2014 | 21 | 4 | N/A | -25 | N/A |
3/31/2014 | 22 | -23 | N/A | -19 | N/A |
12/31/2013 | 21 | -16 | N/A | -17 | N/A |
9/30/2013 | 24 | -8 | N/A | -9 | N/A |
6/30/2013 | 26 | -1 | N/A | -3 | N/A |
3/31/2013 | 27 | 3 | N/A | -4 | N/A |
12/31/2012 | 23 | 0 | N/A | -2 | N/A |
9/30/2012 | 23 | 3 | N/A | -3 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: Insufficient data to determine if LMNL's forecast earnings growth is above the savings rate (2.2%).
Earnings vs Market: Insufficient data to determine if LMNL's earnings are forecast to grow faster than the US market
High Growth Earnings: Insufficient data to determine if LMNL's earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: Insufficient data to determine if LMNL's revenue is forecast to grow faster than the US market.
High Growth Revenue: Insufficient data to determine if LMNL's revenue is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if LMNL's Return on Equity is forecast to be high in 3 years time